These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 3680513)

  • 1. Suppression of hemostatic system activation by oral anticoagulants in the blood of patients with thrombotic diatheses.
    Conway EM; Bauer KA; Barzegar S; Rosenberg RD
    J Clin Invest; 1987 Dec; 80(6):1535-44. PubMed ID: 3680513
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nonvalvular atrial fibrillation: evidence for a prothrombotic state.
    Kahn SR; Solymoss S; Flegel KM
    CMAJ; 1997 Sep; 157(6):673-81. PubMed ID: 9307553
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hemostatic enzyme generation in the blood of patients with hereditary protein C deficiency.
    Bauer KA; Broekmans AW; Bertina RM; Conard J; Horellou MH; Samama MM; Rosenberg RD
    Blood; 1988 May; 71(5):1418-26. PubMed ID: 2965928
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Prothrombin fragment 1+2 (F1+2), thrombin-antithrombin III complex(TAT) and thrombophilia parameters in orally anticoagulated patients with inferior vena cava filters].
    Halbmayer WM; Haushofer A; Toth E
    Wien Med Wochenschr; 1993; 143(5):95-8. PubMed ID: 8511904
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Levels of prothrombin fragment F1+2 in patients with hyperhomocysteinemia and a history of venous thromboembolism.
    Kyrle PA; Stümpflen A; Hirschl M; Bialonczyk C; Herkner K; Speiser W; Weltermann A; Kaider A; Pabinger I; Lechner K; Eichinger S
    Thromb Haemost; 1997 Nov; 78(5):1327-31. PubMed ID: 9408013
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Monitoring "mini-intensity" anticoagulation with warfarin: comparison of the prothrombin time using a sensitive thromboplastin with prothrombin fragment F1+2 levels.
    Millenson MM; Bauer KA; Kistler JP; Barzegar S; Tulin L; Rosenberg RD
    Blood; 1992 Apr; 79(8):2034-8. PubMed ID: 1562730
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The use of prothrombin fragment F1+2 to monitor the effect of oral anticoagulation.
    Bruhn HD; Zurborn KH
    J Heart Valve Dis; 1995 Mar; 4(2):138-40. PubMed ID: 8556173
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Thrombin generation in non-cardioembolic stroke subtypes: the Hemostatic System Activation Study.
    Furie KL; Rosenberg R; Thompson JL; Bauer K; Mohr JP; Rosner B; Sciacca R; Barzegar S; Thornell B; Costigan T; Kistler JP
    Neurology; 2004 Sep; 63(5):777-84. PubMed ID: 15365123
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Congenital antithrombin III deficiency: insights into the pathogenesis of the hypercoagulable state and its management using markers of hemostatic system activation.
    Bauer KA; Rosenberg RD
    Am J Med; 1989 Sep; 87(3B):39S-43S. PubMed ID: 2679069
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Markers of in vivo activation of coagulation. Interrelationships change with intensity of oral anticoagulation.
    Solymoss S; Bovill EG
    Am J Clin Pathol; 1996 Mar; 105(3):293-7. PubMed ID: 8602609
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association between prothrombin activation fragment (F1.2), cerebral ischemia (S-100beta) and international normalized ratio (INR) in patients with ventricular assisted devices.
    Joshi A; Magder LS; Kon Z; Kallam S; Kwon M; Sangrampurkar R; Pierson R; Poston R
    Interact Cardiovasc Thorac Surg; 2007 Jun; 6(3):323-7. PubMed ID: 17669856
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prothrombin fragment F1+2 is not predictive for recurrent venous thromboembolism.
    Kyrle PA; Eichinger S; Pabinger I; Stümpflen A; Hirschl M; Bialonczyk C; Schneider B; Mannhalter C; Melichart M; Traxler G; Weltermann A; Speiser W; Lechner K
    Thromb Haemost; 1997 May; 77(5):829-33. PubMed ID: 9184387
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Relationship between international normalized ratio values, vitamin K-dependent clotting factor levels and in vivo prothrombin activation during the early and steady phases of oral anticoagulant treatment.
    D'Angelo A; Della Valle P; Crippa L; Fattorini A; Pattarini E; Viganò D'Angelo S
    Haematologica; 2002 Oct; 87(10):1074-80. PubMed ID: 12368163
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prothrombin fragment F 1 + 2 and oral anticoagulant therapy.
    Li Z; Wu J; Mammen EF
    Thromb Res; 1994 Sep; 75(6):601-7. PubMed ID: 7831679
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of oral anticoagulant therapy by measuring plasma prothrombin fragment 1 + 2.
    Takahashi H; Wada K; Satoh N; Takakuwa E; Furuta R; Yoshino N; Shibata A
    Blood Coagul Fibrinolysis; 1993 Jun; 4(3):435-9. PubMed ID: 8329570
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The pathophysiology of the prethrombotic state in humans: insights gained from studies using markers of hemostatic system activation.
    Bauer KA; Rosenberg RD
    Blood; 1987 Aug; 70(2):343-50. PubMed ID: 3607275
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effect of very-low-dose warfarin on markers of hypercoagulation in metastatic breast cancer: results from a randomized trial.
    Falanga A; Levine MN; Consonni R; Gritti G; Delaini F; Oldani E; Julian JA; Barbui T
    Thromb Haemost; 1998 Jan; 79(1):23-7. PubMed ID: 9459316
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Elevated levels of prothrombin activation fragment 1 + 2 in plasma from patients with heterozygous Arg506 to Gln mutation in the factor V gene (APC-resistance) and/or inherited protein S deficiency.
    Zöller B; Holm J; Svensson P; Dahlbäck B
    Thromb Haemost; 1996 Feb; 75(2):270-4. PubMed ID: 8815575
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Aging-associated changes in indices of thrombin generation and protein C activation in humans. Normative Aging Study.
    Bauer KA; Weiss LM; Sparrow D; Vokonas PS; Rosenberg RD
    J Clin Invest; 1987 Dec; 80(6):1527-34. PubMed ID: 2824564
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A feasibility study of continuing dose-reduced warfarin for invasive procedures in patients with high thromboembolic risk.
    Larson BJ; Zumberg MS; Kitchens CS
    Chest; 2005 Mar; 127(3):922-7. PubMed ID: 15764777
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.